Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Capital Expenditures (2023 - 2025)

Immunocore Holdings (IMCR) has disclosed Capital Expenditures for 3 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 4.82% to $4.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Dec 2025, down 16.1% year-over-year, with the annual reading at $4.3 million for FY2025, 16.1% down from the prior year.
  • Capital Expenditures hit $4.1 million in Q4 2025 for Immunocore Holdings, up from -$496000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $4.3 million in Q4 2024 to a low of -$496000.0 in Q3 2025.
  • Historically, Capital Expenditures has averaged $1.2 million across 3 years, with a median of $422000.0 in 2024.
  • Biggest five-year swings in Capital Expenditures: surged 430.35% in 2024 and later crashed 727.85% in 2025.
  • Year by year, Capital Expenditures stood at $817000.0 in 2023, then soared by 430.35% to $4.3 million in 2024, then decreased by 4.82% to $4.1 million in 2025.
  • Business Quant data shows Capital Expenditures for IMCR at $4.1 million in Q4 2025, -$496000.0 in Q3 2025, and $414000.0 in Q2 2025.